

RSL/AH

12th October 1984.

Dr. E.L. Harris,  
Department of Health and Social Security,  
Alexander Fleming House,  
Elephant and Castle,  
London SE1 6BY.

Dear Ed,

Further to our telephone conversation, I attach for your attention a copy of page 77 from Plasma Forum 84, the official vehicle of the American Blood Resources Association. In the introductory paragraph, you will see that it is reported that the German government has introduced strict new requirements for plasma importers, and it is interesting to note that ABRA sees this as threatening from a commercial point of view. In fact, ABRA is quite pleased to respond to the German government's stricter requirements since Germany has the available money to pay the higher price that the industry wants.

I repeat the view I made by telephone that the UK should be adopting a similar strict approach to specification of imported labile blood products from all commercial organisations, and a recent discussion on the subject at the Advisory Group on Hepatitis leads me to believe that my views are widely supported.

Our own position in this country is not static and we are actively planning dried heat treatment of all our factor VIII on the empirical basis that it has a satisfactory process efficacy for inactivation of HTLV-III.

I hope we can have an opportunity to talk about this and other matters on plasma supply soon after your return from abroad. //

With best wishes,

Yours sincerely,

GRO-C

R. S. LANE.

78/173

1833